• Home
  • Value Proposition
  • The White Space
  • Operating Model
  • AI & LLM
  • Pipeline
  • Leadership Team
  • Contact Us
  • Mere
    • Home
    • Value Proposition
    • The White Space
    • Operating Model
    • AI & LLM
    • Pipeline
    • Leadership Team
    • Contact Us
  • Home
  • Value Proposition
  • The White Space
  • Operating Model
  • AI & LLM
  • Pipeline
  • Leadership Team
  • Contact Us

Synkrino Development Company

Synkrino Development CompanySynkrino Development CompanySynkrino Development Company

A New Approach to Drug Development

Thousands of medical  breakthroughs never make it past a lab bench. Development failures and irregular financing have become normal and even expected, severely impacting public health while generating mediocre returns. SDC has created novel selection, investment, and divestment mechanisms to bridge the gap between the invention of exceptional, actionable science and the clinics searching for innovative solutions. SDC is developing assets across an array of targets, indications, and modalities, such as an oral mRNA treatment for congenital pediatric disease, a peptide to treat immunotherapy resistant cancers, and a gene therapy platform for single-dose,  adjustable expression of protein therapies.  


The best science needs a path to humans. SDC is the way from point A to point B.

Novel Biotech Financing

Low Risk and Attractive Returns

Drug Development Performance

SDC's novel financing model dynamically advances innovative early to mid-stage therapeutic assets

Drug Development Performance

Low Risk and Attractive Returns

Drug Development Performance

SDC actively designs and manages asset development to clinical and value inflection checkpoints

Low Risk and Attractive Returns

Low Risk and Attractive Returns

Low Risk and Attractive Returns

SDC's orthogonal portfolio reduces risk through biotech investments across technology platforms, biological targets, TAs, and diseases

SDC | At a Glance

6 | Therapeutic assets in initial portfolio

Drug candidates in our initial portfolio include potential treatments for diseases such as Osteo-Arthritis; Obesity, Diabetes and Cardiometabolic Diseases; Immuno-Resistant Tumors; NSCLC; Microvillous Inclusion Disease; and Systemic Sclerosis (SSc) and Lung Fibrosis.

15 | Additional assets in process

The programs we are currently progressing through our funnel include potential treatments for diseases such as Merkel cell carcinoma, non-small cell lung cancer, systemic juvenile idiopathic arthritis, systemic sclerosis, colon cancer, Parkinson's disease, vitiligo, etc.

41 | Pharma experts in SDC network

The combined experience of our team of scientific experts exceed 500 years of drug research and development - therapeutic areas of expertise include but are not limited to anti-retrovirals, auto-immune diseases, neurodegenerative diseases, oncology, cardio-metabolic diseases, etc.

100+ | Assets diligenced

During the last 2 years we have conducted both scientific and commercial diligence of well over 100 individual early-stage biotech programs

10 | Modalities in initial portfolio

The modalities of the initial SDC portfolio include gene therapy, mAbs, protein degraders, bicyclic peptides, macrocycles, GAG mimetic, mRNA, small molecules, etc.

Copyright © 2025 - All Rights Reserved

Leveret af